Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.46 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | CTSK | P43235 | 6/20 | 0.45 |
| ▸ | CTSS | P25774 | 5/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25361007 | 1.00 | KLK5 (0.47) | KLK5PPARAPPARGCTSKCTSS | |
| SCHEMBL3753366 | 1.00 | KLK5 (0.47) | KLK5PPARAPPARGCTSKCTSS | |
| SCHEMBL2632712 | 0.92 | REN (0.51) | CTSKCTSSCTSLCTSB | |
| SCHEMBL19521009 | 0.91 | KLK5 (0.43) | KLK5PPARAPPARGCTSKCTSS | |
| SCHEMBL19521010 | 0.91 | KLK5 (0.43) | KLK5PPARAPPARGCTSKCTSS | |
| SCHEMBL19521011 | 0.91 | KLK5 (0.43) | KLK5PPARAPPARGCTSKCTSS | |
| SCHEMBL8270570 | 0.91 | KLK5 (0.45) | KLK5PPARAPPARGCTSKCTSS | |
| SCHEMBL28684646 | 0.91 | CYP1A2 (0.46) | PPARAPPARGCTSKCTSSCTSL | |
| SCHEMBL28684647 | 0.91 | CYP1A2 (0.46) | PPARAPPARGCTSKCTSSCTSL | |
| SCHEMBL15448116 | 0.90 | PPARA (0.57) | PPARAPPARGCTSKCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551577-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024118524-A1 | AZAINDOLE COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | CEREVEL THERAPEUTICS, LLC (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| CN-113710687-A | Cyclopeptide antibiotics | 豪夫迈·罗氏有限公司 | 2021-11-26 | — | — | CN | disclosed |
| WO-2020185999-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| US-10377772-B2 | Macrocyclic LRRK2 kinase inhibitors | ONCODESIGN S.A. (FR) | 2019-08-13 | — | — | US | disclosed |
| WO-2017189866-A1 | POLYMYXIN ANALOGS USEFUL AS ANTIBIOTIC POTENTIATORS | SPERO OPCO (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2017189866-A1 | POLYMYXIN ANALOGS USEFUL AS ANTIBIOTIC POTENTIATORS | SPERO OPCO (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20170240565-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2017-08-24 | — | — | US | disclosed |
| US-20170240565-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2017-08-24 | — | — | US | disclosed |
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-7790747-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090099205-A1 | Chemokine receptor binding compounds | GENZYME CORPORATION | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377772-B2 | Macrocyclic LRRK2 kinase inhibitors | LRRK2, PINK1, PARK7 | KLK5 2074/4885PPARA 4619/4885PPARG 4423/4885 |
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | KLK5 785/4885PPARA 455/4885PPARG 1675/4885 |
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | CCR5, CXCR3, CCL5 | KLK5 2506/4885PPARA 730/4885PPARG 720/4885 |
| US-20170240565-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PINK1, PARK7 | KLK5 2074/4885PPARA 4619/4885PPARG 4423/4885 |
| US-20090099205-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | KLK5 2506/4885PPARA 730/4885PPARG 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.